SCHEMBL25829281

SCHEMBL25829281

CC(C)(C)OC(=O)Nc1cc(F)cc(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.43
KCNQ4 P56696 3/20 0.41
KCNQ5 Q9NR82 3/20 0.41
RXFP1 Q9HBX9 1/20 0.40
AAK1 Q2M2I8 2/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA9 Q16790 1/20 0.37
RIPK1 Q13546 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
BRD9 Q9H8M2 1/20 0.36
SYK P43405 1/20 0.35
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6124200 0.85 CYP17A1 (0.43) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL3765233 0.84 CYP17A1 (0.44) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL9279023 0.83 CYP17A1 (0.40) CYP17A1KCNQ4KCNQ5RXFP1CA12
SCHEMBL4621173 0.83 CYP17A1 (0.42) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL29021616 0.81 CYP17A1 (0.41) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL29932328 0.81 CYP17A1 (0.41) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL15614546 0.81 MAPT (0.51) CYP17A1KCNQ4KCNQ5RXFP1LMNA
SCHEMBL857284 0.81 HTT (0.55) CYP17A1KCNQ4KCNQ5LMNAPOLB
SCHEMBL30418571 0.80 CYP17A1 (0.38) CYP17A1KCNQ4KCNQ5RXFP1AAK1
SCHEMBL29561754 0.80 CYP17A1 (0.40) CYP17A1KCNQ4KCNQ5RXFP1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. 2023-07-27 US disclosed
WO-2023137007-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. (US) 2023-07-20 WO disclosed
WO-2023137007-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ENANTA PHARMACEUTICALS, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234922-A1 PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID ACE2, HTR3C, SARS1 CYP17A1 476/4885KCNQ4 1477/4885KCNQ5 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.